相关实验视频

Updated: Jul 23, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

在前列腺癌患者的骨F-PSMA-1007吸收

Jorinde Janssen¹, Walter Noordzij², Ton Velleman²

¹Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen 9713GZ, The Netherlands.

Therapeutic advances in medical oncology

|July 13, 2023

概括

在前列腺癌 (PCa) PET/CT扫描中解释骨18F-PSMA-1007吸收的观察者间一致是中度的. 非特异性吸收没有对这一协议产生负面影响,这表明PCa病变的可靠评估.

科学领域:

核医学就是核医学.
放射学放射学是一门学科.
在瘤学瘤学.

背景情况:

对PSMA PET/CT上转移性前列腺癌 (PCa) 病变的准确解释至关重要.
18F-PSMA-1007 PET/CT因其有利的成像特性而越来越多地被使用.
对18F-PSMA-1007的非特异性骨吸收构成了潜在的解释挑战.

研究的目的:

评估PET/CT上报告骨架18F-PSMA-1007吸收的观察者间变异性.
评估非特异性吸收对诊断协议的影响.

主要方法:

分析了来自21名初级PCa和12名生化复发患者的33个18F-PSMA-1007 PET/CT扫描.
三名观察员独立评估了85个骨病变,以确定恶性瘤的可能性.
在患者和病变水平上使用卡帕分析量化了观察者间的变化.

主要成果:

对于骨病变恶性病变的评估,观察者之间观察到适度的一致性 (κ=0.54患者水平, κ=0.55病变水平).
没有CT相关性的病变主要被评为非恶性病变 (95-100%).
额外的成像并没有改善观察者之间的一致性 (κ=0.39损伤水平).

结论:

对体18F-PSMA-1007吸收的观察者间一致性是中度的,与现有文献一致.
不特定的骨吸收,一个已知的陷,在本研究中没有破坏观察者之间的协议.
标准化解释准则可能进一步提高报告PCa病变的一致性.

关键词:

在18F-PSMA-1007中使用.在PSMA PET/CT中使用.观察者之间的协议.前列腺癌是前列腺癌.骨的吸收是如何发生的

更多相关视频

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of ⁶⁸Ga-Labelled Nano Molecules

Published on: October 4, 2024

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET